Clinical Trials Directory

Trials / Unknown

UnknownNCT05742061

Intra-articular Platelet Rich Plasma vs Corticosteroid in Treatment of Knee Osteoarthritis Patients

Intra-articular Platelet Rich Plasma vs Corticosteroid in Treatment of Knee Osteoarthritis

Status
Unknown
Phase
EARLY_Phase 1
Study type
Interventional
Enrollment
100 (estimated)
Sponsor
Benha University · Academic / Other
Sex
All
Age
40 Years – 70 Years
Healthy volunteers
Accepted

Summary

Knee osteoarthritis is the most common type of osteoarthritis in the lower extremity and constitutes 23% of all arthritis cases, about 13% of females and 10% of males aged above 60 years have symptomatic knee OA. Intra-articular corticosteroids (IACs) are a frequently-used treatment regimen for pain relief from symptomatic knee OA as it inhibits inflammation and reduces prostaglandin synthesis. Platelet-rich plasma (PRP) is an autologous blood product containing a high percentage of various growth factors (GFs), such as fibroblast growth factor, epidermal growth factor, vascular endothelial growth factor, transforming growth factor-β and platelet-derived growth factor. The aim of this study is to compare effect of intra-articular injection of platelet rich plasma versus corticosteroid in treatment of primary knee osteoarthritis.

Conditions

Interventions

TypeNameDescription
DRUGCorticosteroidThe injection will be given at a site near the superolateral pole of patella in the suprapatellar pouch under aseptic conditions and the patient will be advised to take one day of rest after injection and apply ice to the area if there are any signs of inflammation.
OTHERPlatelet Rich PlasmaPRP preparation :- 20 ml of venous blood will be drawn from the antecubital vein using an 18G needle to avoid traumatizing platelets and will be collected in a sterile tube containing 2 ml of Sodium Citrate anticoagulant. Approximately 2 ml of whole blood will be separated for a complete blood count.The blood with anticoagulant will centrifuged at 4000 rpm for 6-10 minutes to separate erythrocytes and then at 4000 rpm for 6-10 min to concentrate platelets.The final product was 4-5 ml of PRP containing leukocytes with platelet concentration of 3-5 times the average normal value.

Timeline

Start date
2023-04-01
Primary completion
2023-10-01
Completion
2023-12-01
First posted
2023-02-23
Last updated
2023-02-23

Source: ClinicalTrials.gov record NCT05742061. Inclusion in this directory is not an endorsement.